Baird Capital Portfolio Company Strata Oncology Secures $26M in Series B Funding

Baird Capital portfolio company Strata Oncology, a Michigan-based precision oncology platform company, today announced the close of a $26 million USD Series B funding round. New investors Pfizer Ventures, Merck Global Health Innovation Fund and Renaissance Venture Capital Fund were joined by existing investors Arboretum Ventures and Baird Capital.

For more information on how Strata Oncology will use the new funding, please read the full news release here.